Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
188.07
-1.98 (-1.04%)
At close: Jul 21, 2025, 4:00 PM
192.10
+4.03 (2.14%)
After-hours: Jul 21, 2025, 7:59 PM EDT
Danaher Revenue
Danaher had revenue of $5.74B in the quarter ending March 28, 2025, a decrease of -0.95%. This brings the company's revenue in the last twelve months to $23.82B, up 0.35% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$23.82B
Revenue Growth
+0.35%
P/S Ratio
5.72
Revenue / Employee
$378,095
Employees
63,000
Market Cap
134.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
DHR News
- 4 days ago - 45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs - Seeking Alpha
- 21 days ago - Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside - Seeking Alpha
- 24 days ago - Danaher Appoints Martin Stumpe as Chief Technology and AI Officer - PRNewsWire
- 24 days ago - Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences - PRNewsWire
- 4 weeks ago - Danaher: High Capex And Low Debt Despite Trump Legislation - Seeking Alpha
- 4 weeks ago - Danaher Schedules Second Quarter 2025 Earnings Conference Call - PRNewsWire
- 6 weeks ago - Prosperity Partners Completes Acquisition of Danaher Attig & Plante - Business Wire
- 7 weeks ago - SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations - Business Wire